. Author manuscript; available in PMC: 2017 Jul 1.

Published in final edited form as: Ann Biomed Eng. 2016 Jan 5;44(7):2251–2260. doi: 10.1007/s10439-015-1518-x

Table II.

OCT measurements in stent groups at baseline and follow-up

	Number	Treatment Group
		Malapposed	Apposed
		10	3	p-value
OCT	*Cross-Sectional Measures*			^ significant at the 5% level*
OCT	*Cross-Sectional Measures*
Baseline	Mean Reference Lumen CSA [mm2]	7.50 ± 1.10	6.51 ± 0.56	0.0747
	Mean Stent CSA [mm2]	6.30 ± 0.47	6.95 ± 0.96	0.5059
	Stent Overexpansion [Max Stent CSA / Mean Lumen Ref CSA]	1.00 ± 0.14	1.18 ± 0.11	0.0878
	Stent Overexpansion [Max Stent CSA / Mean Lumen Ref CSA]
	Stent Underexpansion [Min Stent CSA / Mean Lumen Ref CSA]	0.71 ± 0.18	0.92 ± 0.06	0.0102 ^*
	Stent Underexpansion [Min Stent CSA / Mean Lumen Ref CSA]
	*Strut-Level Measures*
	Number of Struts	6955	1469
	Number of Malapposed Struts	2153	11
	Number of Apposed Struts	4802	1458
	Max Wall Distance [mm]	0.51 ± 0.23	0.09 ± 0.05	0.0002 ^*
	Mean Wall Distance [mm]	0.11 ± 0.08	−0.02 ± 0.01	0.0070 ^* Mann-Whitney
Acute [5 days]	Number of Struts	6366	1289
	Number of Malapposed Struts	27	2
	Number of Apposed Struts	6339	1287
	Max Wall Distance [mm]	0.15 ± 0.06	0.09 ± 0.05	0.1612
	Mean Wall Distance [mm]	−0.01 ± 0.01 ⁺	−0.01 ± 0.02	0.9909
	Mean Stent CSA [mm²]	6.03 ± 0.50 ⁺	6.46 ± 0.45 ⁺	0.2357
	Stent Underexpansion [Min Stent CSA / Mean Lumen Ref CSA]	0.66 ± 0.18 ⁺	0.87 ± 0.05	0.0078 ^*

significant at the 5% level

⁺

Different to Baseline at 5% level of significance